STAT+: Pharmalot: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more

Summary: The FDA is making some big changes. Under Commissioner Marty Makary, the agency promised to be super open with the public. But lately, they are holding far fewer public meetings. In fact, meetings about new drugs dropped by 72% last year! Many scientists are leaving the agency, and politicians are getting more involved in medical choices.

On the bright side, the FDA is making it easier and cheaper for companies to create "biosimilars." These are copycat versions of expensive medicines. By cutting some testing rules, companies can save $20 million per drug. This should help lower medicine costs for Americans and help the U.S. catch up to Europe.

For more details, see statnews at statnews.com/pharmalot/2026/03/09/fda-biosimilars-prasad-novo-hims-weight-wegovy/?utm_campaign=rss (opens in new tab)